Silence Therapeutics plc (SLN) Form 424B5 — May 27, 2026
Silence Therapeutics plc (SLN) has filed a prospectus supplement for an 'at-the-market' equity offering of up to $100 million in American Depositary Shares (ADSs) through sales agent Jefferies LLC. The offering allows the company to sell shares from time to time at prevailing market prices, with no minimum or maximum sales price required, providing flexibility but creating uncertainty regarding the final dilution impact. The filing discloses that as of March 31, 2026, the company had a net tangible book value of $38.5 million, or $0.82 per ADS.
Key figures
- Cash Position
- 38500000
- Gross Proceeds
- 100000000
- Offering Price
- 6.1
- Shares Offered
- 16393442
- Shares Outstanding
- 47234613
- Commission rate
- 3.0%
- Dilution per ads
- 3.98
- Estimated expenses
- 750000
- Adjusted ntbv per ads
- 2.12
- Net tangible book value per ads
- 0.82
Price after filing
Close on the filing date to close N calendar days later (from $6.80). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.